In summary, our results indicate the UGT1A1*28 allele has no significant effect on the pharmacokinetics of silybin A and silybin B in patients with NAFLD or chronic HCV infection. This evidence concerns the gene UGT1A1 and metabolic dysfunction-associated steatotic liver disease.